Medicaid Proposal Basing Best Price On ‘Stacked’ Discounts At Odds With Law, US Legislators Say

Republicans in Congress also amplify biopharma concerns with provisions in a Medicaid proposed rule that would require cell and gene therapy developers to justify pricing through an agency-conducted audit and that could subject drugs that are bundled with services to Medicaid rebate requirements.